<DOC>
	<DOCNO>NCT00574093</DOCNO>
	<brief_summary>This study design evaluate effect Visudyne® combination therapy ( Visudyne® [ verteporfin injection ] Lucentis™ ) visual acuity outcome . Study result submit publication provide data may help physician refine clinical management patient CNV secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Efficacy Safety Study Lucentis ( Ranibizumab ) Visudyne ( Verteporfin ) Combination Therapy Neovascular AMD</brief_title>
	<detailed_description>This single arm study . Patients administer Lucentis™ Day 1 , Months 1 2 , need interval least 30 day Month 11 base retreatment criterion algorithm . These patient also administer Visudyne® Day 3 . Consenting patient participate Screening Period evaluate study eligibility . Patient eligibility assessment include BCVA , contrast sensibility , speed read VFQ-25 , standard ophthalmic examination , OCT , color fundus photography , Fluorescein Angiography ( FA ) , Green Indocyanine Angiography , Microperimetry multifocal ERG . BCVA mean central retinal thickness measure OCT repeat every follow visit . Fluorescein Angiography ( FA ) , Green Indocyanine Angiography , contrast sensibility speed read mean retinal sensitivity measure microperimetry repeat month 3 , 6 , 9 12 month . Color fundus photography month 1 , 3 , 6 , 9 12 month . Multifocal ERG repeat month 3 12 month . VFQ-25 repeat month 3 12 . The patient receive ranibizumab monthly unless BCVA get bad 5 letter baseline BCVA / mean central retinal thickness evaluate OCT increase less 100 µm compare month 2 visit ( last date treatment ) . The repetition dose ranibizumab begin thirtieth day follow end previous treatment .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>50 year old male female patient race subfoveal CNV secondary AMD ( type lesion ) . The total area CNV encompass within lesion must &gt; 50 % total lesion area . The total lesion area must greatest linear dimension ≤5400 micron ( 9 MPS Disc Areas ) . BCVA letter score study eye 73 24 ( approximately 20/40 20/320 Snellen Equivalent ) use ETDRS chart measure 4 meter distance . Any prior treatment Visudyne , Macugen , Lucentis ( Ranibizumab ) , Avastin ( Bevacizumab ) antiangiogenic corticosteroid intravitreal treatment study eye Prior externalbeam radiation , subfoveal focal laser photocoagulation , transpupillary thermotherapy , par plana vitrectomy study eye History intraocular surgery study eye except uncomplicated cataract surgery 90 day prior treatment History YAGlaser posterior capsulotomy study eye within 30 day prior treatment Use non steroid antinflammatory drug study Presence angioid streak , presume ocular histoplasmosis syndrome , pathologic myopia ( &gt; 8 D ) Presence fibrosis , haemorrhage , pigment epithelial detachment hypofluorescent lesion obscure great 50 % CNV lesion Tear ( rip ) retinal pigment epithelium Vitreal haemorrhage , retinal detachment macular hole Epiretinal membrane Uncontrolled glaucoma study eye ( defined intraocular pressure ≥ 25 mmHg despite treatment two topical pharmacological antiglaucomatous medication ) Active history ocular inflammation infection Aphakia posterior capsule tear Pregnant nursing ( lactate ) woman Women childbearing potential unless meet follow definition postmenopausal Any systemic medical condition may interfere safety patient Positive anamnesis tumor last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>combination therapy</keyword>
	<keyword>Lucentis</keyword>
	<keyword>Visudyne</keyword>
</DOC>